180 Life Sciences Corp. (NASDAQ:ATNF – Get Free Report) was the recipient of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 17,100 shares, a decline of 59.7% from the March 31st total of 42,400 shares. Based on an average daily volume of 103,100 shares, the short-interest ratio is currently 0.2 days. Currently, 3.3% of the shares of the company are short sold.
180 Life Sciences Stock Performance
Shares of NASDAQ ATNF traded up $0.03 during mid-day trading on Friday, reaching $1.80. 20,610 shares of the company were exchanged, compared to its average volume of 75,451. The company’s 50-day simple moving average is $2.82 and its 200-day simple moving average is $4.62. 180 Life Sciences has a twelve month low of $1.33 and a twelve month high of $27.93.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in 180 Life Sciences stock. Armistice Capital LLC bought a new stake in 180 Life Sciences Corp. (NASDAQ:ATNF – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 131,000 shares of the company’s stock, valued at approximately $80,000. Armistice Capital LLC owned about 2.46% of 180 Life Sciences at the end of the most recent quarter. Institutional investors and hedge funds own 4.07% of the company’s stock.
About 180 Life Sciences
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.
Featured Articles
- Five stocks we like better than 180 Life Sciences
- Do ETFs Pay Dividends? What You Need to Know
- MarketBeat Week in Review – 4/22 – 4/26
- 3 REITs to Buy and Hold for the Long Term
- 3 Stocks Leading the U.S. Agriculture Comeback
- Why is the Ex-Dividend Date Significant to Investors?
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for 180 Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 180 Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
